Carregant...
Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens
Prostate cancers, initially responsive to anti-androgen therapies, often advance to a hormone-refractory “castrate resistant” stage (CRPC). However the androgen receptor (AR) pathway remains active and key for cell growth and gene expression within tumours, even in the apparent absence of hormone. P...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3427022/ https://ncbi.nlm.nih.gov/pubmed/22179832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2011.591 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|